ERBBal Remedies: Combination Therapy for <i>EGFR</i>-mutant Lung Cancers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30135146.
- Also identified by DOI 10.1158/1078-0432.CCR-18-2179.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Multiple members of the ERBB/HER family of the receptor tyrosine kinases have been implicated in mediating acquired resistance to EGFR inhibitors that are used to treat <i>EGFR</i>-mutant lung cancers. New single agents and combination therapies targeting the ERBB/HER family members are being investigated to either prevent or overcome the emergence of acquired resistance. <i>Clin Cancer Res; 24(22); 5499-501. ©2018 AACR</i> <i>See related article by Romaniello et al., p. 5610</i>.
Medical subject headings
- ErbB Receptors
- Lung Neoplasms